

Peer Review

# Review of: "Efficacy and Safety of CTLA-4, PD-1, and LAG-3 Immune Checkpoint Inhibitors as Monotherapy and Combination Therapy in Advanced Melanoma: A Systematic Review and Meta-Analysis"

Kevinn Eddy<sup>1</sup>

1. Independent researcher

Khan et al. in this well-written manuscript describe the role of mature clinical efficacy and safety profile data of CTLA-4, PD-1, and PD-L1 inhibitors as individual therapy or combination therapy. To enhance the manuscript, the authors should make the following revisions.

The most updated epidemiology statistics must be used from the year 2025 in the introduction's first paragraph about the diagnosis, cases, and death rates.

## Declarations

**Potential competing interests:** No potential competing interests to declare.